Maruyama M, Noda T, Kiyozuka Y, Okamura Y, Ibaraki T, Katou Y, Ninomiya Y, Oku M, Nabuchi K, Hino K
Dept. of Obsterics and Gynecology, Nara Medical Univ.
Gan No Rinsho. 1987 Oct;33(12):1507-14.
A case is reported of a 34-year-old female who complained of an adult head-sized tumor in the pelvis and was treated with a high dose of CDDP. On the first look operation, it was found impossible to perform reduction surgery because of severe adhesion and peritonitis carcinomatosa. To introduce a high concentration of an anti-cancer agent into the tumor tissue, we administered CDDP intravenously, intraperitoneally and intra-arterially to the total amount of 1815 mg. After this high dose combination chemotherapy, a second look operation was performed and the tumor was seen to be reduced. The patient is now in remission and is being followed up as an out-patient. The clinical course of this case had decided for us which route would be the most effective and would have the least side effect, also, how much of a dosage can be administered as a maximum adoptive dose of an anti-cancer agent, and what kind of a second-line chemotherapy is effective against resistant cancer cells.
报告了一例34岁女性病例，该患者主诉盆腔有一个成人头部大小的肿瘤，并接受了高剂量顺铂治疗。在初次手术时，由于严重粘连和癌性腹膜炎，发现无法进行肿瘤切除手术。为了将高浓度抗癌药物引入肿瘤组织，我们通过静脉、腹腔和动脉途径给予顺铂，总量达1815毫克。经过这种高剂量联合化疗后，进行了二次探查手术，发现肿瘤缩小。患者目前处于缓解期，作为门诊患者接受随访。该病例的临床过程为我们确定了哪种给药途径最有效且副作用最小，同时也确定了作为抗癌药物最大耐受剂量可以给予多少剂量，以及哪种二线化疗对耐药癌细胞有效。
